ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market

NewMediaWire01-02

FREMONT, CA - (NewMediaWire) - January 2, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in ophthalmology, neurology, and oncology/hematology, is ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500924951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 22:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500924951","market":"us","top_or_hot":-1,"title":"ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market","media":"NewMediaWire","content":"<div>\n<p>FREMONT, CA - (NewMediaWire) - January 2, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in ophthalmology, neurology, and oncology/hematology, is ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abvc-biopharma-secures-additional-patent-140000595.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-02 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/abvc-biopharma-secures-additional-patent-140000595.html><strong>NewMediaWire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FREMONT, CA - (NewMediaWire) - January 2, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in ophthalmology, neurology, and oncology/hematology, is ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abvc-biopharma-secures-additional-patent-140000595.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4022","symbol_name":"陆运","start_time":0,"source_url":"https://finance.yahoo.com/news/abvc-biopharma-secures-additional-patent-140000595.html","article_id":"2500924951","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500924951","pubTimestamp":1735826400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"This patent adds to ABVC's prior successes, including similar patents granted by the United States Patent and Trademark Office  in 2021 and the Australian Patent Office  in 2024. These approvals collectively reinforce ABVC's strength in developing natural, botanical-based therapies for ADHD.The patented treatment, utilizing Polygala tenuifolia extract, represents a novel approach to addressing the core symptoms of ADHD through its Norepinephrine Transporter  inhibition mechanism. This innovative solution holds promise for patients inadequately managed by existing therapies.\"Strengthening Our Global Position in ADHD Innovation\"\"The approval of this patent in Taiwan is a testament to our commitment to advancing ADHD care,\" said Dr. Uttam Patil, ABVC Chief Executive Officer. \"With patents now granted in three key jurisdictions, we are strategically positioned to expand the global reach of this groundbreaking therapy, in an effort to improve outcomes for patients worldwide.\". Forward-Looki","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4022":"陆运","BK4560":"网络安全概念","R":"瑞德系统","BK4232":"货物陆运","BK4548":"巴美列捷福持仓","BK4202":"服装、服饰与奢侈品","CAGR":"California Grapes International, Inc.","WRD":"文远知行","BK4554":"元宇宙及AR概念","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","PHH":"Park Ha Biological Technology Co. Ltd.","BK4585":"ETF&股票定投概念","FORD":"福沃德工业","BK4139":"生物科技","BK4159":"经销商","ADHD":"Alcobra Ltd.","BK4116":"互联网服务与基础架构","ABVC":"ABVC BioPharma, Inc.","NET":"Cloudflare, Inc.","BK4588":"碎股"},"translate_title":"除了已授予的美国和澳大利亚专利外，ABVC BioPharma还获得了一项ADHD治疗专利，向321.4亿美元潜在市场的全球专利版图迈进","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADHD":1,"WRD":1,"R":1,"PHH":1,"NET":1,"FORD":1,"CAGR":1,"ABVC":1},"content_text":"FREMONT, CA - (NewMediaWire) - January 2, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in ophthalmology, neurology, and oncology/hematology, is announcing the approval of its patent application by Taiwan's Intellectual Property Office (TIPO). The patent, titled \"Polygala Extract for Treating Attention Deficit Hyperactivity Disorder (ADHD)\" (Application No. 110106546), marks a significant milestone in ABVC's global intellectual property portfolio.\nThis patent adds to ABVC's prior successes, including similar patents granted by the United States Patent and Trademark Office (US Patent No. 17/120,965) in 2021 and the Australian Patent Office (Patent No. 2021403197) in 2024. These approvals collectively reinforce ABVC's strength in developing natural, botanical-based therapies for ADHD.\nThe patented treatment, utilizing Polygala tenuifolia extract, represents a novel approach to addressing the core symptoms of ADHD through its Norepinephrine Transporter (NET) inhibition mechanism. This innovative solution holds promise for patients inadequately managed by existing therapies.\n\"Strengthening Our Global Position in ADHD Innovation\"\"The approval of this patent in Taiwan is a testament to our commitment to advancing ADHD care,\" said Dr. Uttam Patil, ABVC Chief Executive Officer. \"With patents now granted in three key jurisdictions, we are strategically positioned to expand the global reach of this groundbreaking therapy, in an effort to improve outcomes for patients worldwide.\"\nMarket Potential and Next StepsABVC is actively advancing its ADHD therapy, which is encapsulated in its proprietary drug asset ABV-1505. The treatment has already completed Phase IIa clinical trials, with Phase IIb results expected soon. As per Polaris market research, the global ADHD treatment market is projected to grow from $16.13 billion in 2022 to $32.14 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.1%.[1]\nThe Company plans to leverage this robust IP foundation to pursue further clinical studies, regulatory clearances, and strategic partnerships globally.\nAbout ABVC BioPharma & Its IndustryABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct global clinical trials through Phase III.\nForward-Looking StatementsThis press release contains \"forward-looking statements.\" Such statements may be preceded by the words \"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\" \"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential,\" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\nThis press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.\nContact:Uttam PatilEmail: uttam@ambrivis.com\n[1] https://www.prnewswire.com/news-releases/global-attention-deficit-hyperactivity-disorder-adhd-market-size-projected-to-reach-usd-32-14-billion-by-2032--with-cagr-of-7-1-study-by-polaris-market-research-301729196.html#:~:text=According%20to%20the%20research%20report\nView the original release on www.newmediawire.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500924951"}